Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 8 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Maragouli, Elena  [Clear All Filters]
Journal Article
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., & Huang H. (2017).  Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?. J Thorac Dis. 9(9), 2771-2773.
Sapalidis, K., Zarogoulidis P., Petridis D., Kosmidis C., Fyntanidou B., Tsakiridis K., et al. (2019).  EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE ®. Journal of Cancer. 10(20), 4739 - 4746.
Sapalidis, K., Zarogoulidis P., Petridis D., Kosmidis C., Fyntanidou B., Tsakiridis K., et al. (2019).  EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE.. J Cancer. 10(20), 4739-4746.
Zarogoulidis, P., Chinelis P., Efthymiou C., Athanasiadou A., Mpikos V., Papatsibas G., et al. (2017).  EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.. Respir Med Case Rep. 22, 7-10.
Alexidis, P., Karatzoglou S., Dragoumis D., Drevelegas K., Tzitzikas I., Hatzimouratidis K., et al. (2020).  Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer.. J Cancer. 11(5), 1008-1016.
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y-G., et al. (2018).  Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.. Transl Lung Cancer Res. 7(Suppl 1), S28-S30.
Alexidis, P., Dragoumis D., Karatzoglou S., Drevelegas K., Tzitzikas I., Hatzimouratidis K., et al. (2019).  The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial.. J Cancer. 10(25), 6217-6224.
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Karapantzos I., Bai C., et al. (2018).  Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy.. Transl Lung Cancer Res. 7(Suppl 1), S46-S48.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.